Hims & Hers' persistence in selling high-margin compounded GLP-1s, even as shortages ease, is a strategic choice born of necessity. Switching to low-margin branded drugs ($10-15 profit per script) would collapse their business model, making the high-risk strategy a "financial Hail Mary."

Regulators cracked down on Hims not solely for selling compounded GLP-1s, but because of a confluence of provocative actions. A highly visible Super Bowl ad and a bold oral pill launch created a perception of 'thumbing the nose' at regulators and Novo Nordisk, forcing a decisive response.

Despite its first-mover advantage, Novo Nordisk lost its lead in the weight-loss drug market by failing to recognize its consumer-driven nature. While it planned a traditional pharma launch, competitor Eli Lilly adopted a direct-to-consumer model, treating the drug like an e-commerce product and capturing the market.

The two pharma giants are competing aggressively in the direct-to-consumer channel. They're cutting prices on their GLP-1 drugs, anticipating that lower costs will drive significantly higher volume and sales in the long run, even if it hurts short-term revenue forecasts.

The emergence of low-cost, compounded versions of GLP-1 drugs from telehealth companies like Hims is creating significant pricing pressure on market leaders Novo Nordisk and Eli Lilly. This dynamic has pushed the pharma giants toward direct-to-consumer models with lower prices to compete.

Novo Nordisk's head-to-head trial of its Cagracemma against Lilly's Zepbound was a major strategic error. Instead of demonstrating superiority, the study showed Zepbound was more effective, wiping $26 billion from Novo's market cap. Novo effectively funded a large-scale clinical trial that validated its primary competitor's product.

The obesity drug market is seeing prices cut in half much faster than anticipated, despite being a duopoly. This rapid price degradation is driven by Novo Nordisk, the market laggard, aggressively using price as a weapon to reclaim market share from Eli Lilly, a dynamic typically seen only after multiple new players enter.

Novo priced the maintenance dose of its oral Wegovy pill far lower than anticipated. This aggressive strategy, costing less than the average U.S. monthly grocery bill (~$400), is a direct attempt to regain momentum from rival Eli Lilly and expand the self-pay market before more oral competitors launch.

Vivtex's $2.1B deal with Novo Nordisk wasn't from a single pitch; it was cultivated over many years, stemming from pre-existing academic relationships. The key was building mutual scientific trust by consistently sharing progress—and even failures—allowing Novo Nordisk to observe their journey long-term.